VRNA Form 4: CEO disposes 12.18M shares; RSUs converted to $107/ADS
Rhea-AI Filing Summary
Director and CEO David Zaccardelli reported multiple transactions tied to the company’s scheme of arrangement with Merck/Parent that closed at the effective time. On 10/07/2025 large blocks of Ordinary Shares and restricted share units were converted and/or disposed for cash consideration of $13.375 per Ordinary Share (equivalent to $107 per ADS). The filing shows dispositions totaling 12,176,144 Ordinary Shares and additional conversions of time‑based and performance RSUs into cash, with certain PRSUs resulting in a retained beneficial position of 1,649,952 Ordinary Shares (presented as underlying ADSs) after the transactions. Transactions were executed pursuant to the Transaction Agreement dated 07/08/2025, and amounts were paid net of applicable withholding taxes.
Positive
- Cash consideration specified at $13.375 per Ordinary Share ($107 per ADS) provides clear, fixed payout terms
- RSUs and PRSUs fully vested/converted at the effective time, enabling definitive cash settlement
Negative
- Substantial disposals of 12,176,144 Ordinary Shares materially reduced reported direct holdings
- Executive equity alignment materially decreased post‑transaction, with several positions showing 0 beneficial ownership after the disposals
Insights
Executive holdings largely cashed out under the scheme, with limited retained RSU value.
The reporting shows the President and CEO executed sizable disposals and RSU conversions as part of a scheme of arrangement that set consideration at $13.375 per Ordinary Share ($107 per ADS). Several time‑based and performance RSUs were accelerated and converted into cash at the effective time under the Transaction Agreement dated 07/08/2025.
This reduces insider equity exposure and transfers economic value to the reporting person in cash. Investors monitoring insider alignment should note the near‑term change in executive ownership and any remaining contingent RSU positions, including the retained 1,649,952 Ordinary Shares-equivalent from one PRSU conversion.
Scheme consideration produced immediate cash settlement of equity awards and shareholdings.
The Transaction Agreement required outstanding time‑based RSUs and earned PRSUs to vest or convert into a cash payment equal to the ADS Consideration ($107 per ADS) multiplied by underlying ADSs. The filing lists multiple RSU/PRSU conversions and cash payments, including aggregate RSU conversions of 3,285,280 and PRSU-related amounts totaling several hundred thousand ADS equivalents that were paid in cash.
For deal accounting and payout timing, stakeholders should reference the effective date 10/07/2025 and expect the cash settlements to be net of withholding taxes per the agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 800,000 | $0.00 | -- |
| Exercise | Restricted Share Unit | 389,792 | $0.00 | -- |
| Exercise | Restricted Share Unit | 445,536 | $0.00 | -- |
| Grant/Award | Restricted Share Unit | 1,649,952 | $0.00 | -- |
| Exercise | Restricted Share Unit | 1,649,952 | $0.00 | -- |
| Disposition | Ordinary Shares | 12,176,144 | $0.00 | -- |
| Exercise | Ordinary Shares | 3,285,280 | $0.00 | -- |
| Disposition | Ordinary Shares | 3,285,280 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration.
